An Operationally Seamless Phase 2/3, Randomized, Active -Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Virologically Suppressed People With HIV-1
This study is looking at a new way to treat HIV, using a pill taken once a week instead of daily. It's for adults whose HIV is already well-managed with their current medication. Researchers want to compare the safety and effectiveness of this new weekly pill combination (GS-1720 with GS-4182) against a common daily treatment called Biktarvy. The main aim is to see if the new weekly treatment can keep the amount of HIV in the blood very low, just as well as the daily treatment. They will also look at any side effects and how the new treatment affects the immune system.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This research study is about finding better ways to manage HIV. HIV treatments have come a long way, but most people still need to take pills every day. This study is testing a new treatment that you would only need to take once a week. Imagine having to take your medication only once a week instead of every single day – it could make managing HIV much easier for many people.
The study involves two new medications, GS-1720 and GS-4182, which will be given together as a weekly treatment. These will be compared to a well-known daily HIV medication called Biktarvy, which has been proven to work well. The main goal is to see if this new weekly treatment is just as good at keeping the amount of HIV virus in the blood very low (which means the treatment is working) and if it's safe to use.
This study will help us understand if a weekly HIV treatment can be a good option for people whose HIV is already under control. Finding simpler ways to take medication can make a big difference to people's lives, making it easier to stick to their treatment plan and live well with HIV.
النقاط الرئيسية
- This study tests a new weekly HIV pill.
- It's for adults whose HIV is already well-controlled.
- Compares the new weekly pill to a standard daily treatment (Biktarvy).
- Aims to check safety and how well it keeps HIV levels low.
- Participation involves regular clinic visits for blood tests and health checks.
- Could offer a simpler way to manage HIV in the future.
من قد يكون مؤهلاً؟
للانضمام إلى هذه الدراسة، يجب أن تكون بالغًا، بعمر 18 عامًا أو أكثر. يُرحب بمشاركة كل من الرجال والنساء.
Crucially, your HIV needs to be well controlled already. This means that your current HIV treatment should be working effectively, and the amount of HIV virus in your blood should be very low.
There might be other specific health checks or conditions that determine if you can join, which the study team will discuss with you. These are put in place to ensure your safety and that the study results are clear.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- هل عمرك 18 سنة أو أكثر؟
- Is your HIV already being managed well by your current treatment?
- Is the amount of HIV virus in your blood currently very low?
- Are you able to attend regular clinic appointments for about 1 to 2 years?
ماذا يتضمن المشاركة؟
If you decide to take part in this study, you will be given either the new weekly pill combination (GS-1720 with GS-4182) or the daily Biktarvy medication. This decision will be made randomly, like flipping a coin.
You will have regular visits to the clinic over a period of about 1 to 2 years. During these visits, the study team will check your health, take blood samples to measure your HIV levels and immune cells, and ask about any side effects you might be experiencing. These checks are important to see how well the treatment is working and to make sure it's safe for you. The total duration of your participation in the study could be up to 96 weeks (about 1 year and 10 months).
المخاطر والفوائد المحتملة
المواقع (6)
- —غير مؤكدفرنسا
- —غير مؤكدألمانيا
- —غير مؤكدبولندا
- —غير مؤكدالسويد
- —غير مؤكدإسبانيا
- —غير مؤكدإيطاليا
أسئلة شائعة
What is HIV-1 RNA?
HIV-1 RNA is a way we measure how much of the HIV virus is in your blood. A low number, especially below 50, means the treatment is working well.
What does 'virologically suppressed' mean?
This means that the HIV virus in your blood is at a very low level because your current treatment is working effectively to control it.
What's the difference between Phase 2 and Phase 3?
Phase 2 studies mainly look at safety and if the treatment works. Phase 3 studies involve more people and compare the new treatment to existing ones to confirm safety and effectiveness on a larger scale.
What is Biktarvy?
Biktarvy is a common and effective daily medication that many people with HIV already take to keep the virus under control.
Will I know if I'm getting the new weekly pill or Biktarvy?
No, it's a 'blinded' study, meaning neither you nor your study doctor will know which treatment you are receiving. This helps make the study results fair.
كيفية معرفة المزيد
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.